Search
Oxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations. … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14mlPectin
go.drugbank.com/drugs/DB11158ApprovedInvestigationalVet approved[L1961] The carboxylic group of the constituents of pectin can exist in the form of esters, free acids, ammonium, potassium or sodium salts or as acid amides. … Under the FDA regulation, pectin qualifies as a GRAS (generally recognized as safe) food substance. This status allows pectin to be used with no limitations.[L1960]
Mixtures: Diban Cap, Diban CapCategories: Compounds used in a research, industrial, or household settingErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSynonyms: co-dergocrine mesilate, co-dergocrine mesylateAmbroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalSurfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. … It stimulates synthesis and release of surfactant by type II pneumocytes.
Synonyms: N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol, N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanolMixtures: TUSIGEN NF, HISTIACIL NFPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function, … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, Programmed Death Receptor-1 Blocking AntibodyAngiotensin-converting enzyme
go.drugbank.com/bio_entities/BE0000221TargetEnzymeHumansDipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation … Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the
Synonyms: Dipeptidyl carboxypeptidase IBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigationalimmune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can occasionally be fatal. … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-((2-Ethoxyphenoxy)methyl)morpholineDNA ligase 1
go.drugbank.com/bio_entities/BE0000199TargetHumansDNA ligase that seals nicks in double-stranded during DNA repair (PubMed:30395541). Also involved in DNA replication and DNA recombination
Synonyms: DNA ligase I